GlassScriptPhysician profile
Tina Yang
NPI 1023082740
$13,774.12
in general payments reported to CMS, 2019-2025
46 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $2,763 · 2021: $2,449 · 2022: $1,808 · 2023: $1,847 · 2024: $1,315 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,611 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,611.26 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,362.82 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $2,271.57 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,146.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $624.56 | 2019-2024 | Ozempic, Rybelsus |
| Allergan, INC. | $614.93 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $604.18 | 2021-2025 | |
| Amarin Pharma, INC. | $595.32 | 2019-2021 | |
| Pfizer INC. | $585.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.40 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $461.51 | 2019-2025 | Trintellix |
| Lundbeck LLC | $451.95 | 2022-2023 | Rexulti |
| Horizon Therapeutics Plc | $428.43 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.11 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $391.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $260.74 | 2019-2025 | Krystexxa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.